on morning, cancer. trial that in announced start everyone. the III I'll that a independent reminder Thanks, analysis, treat or that recommended II Andrew, to trial the good we overall PRESERVE progress final and the triple-negative committee trial survival continue recent conducted this and the Phase to of X from population. analysis month, breast the for the Earlier interim monitoring metastatic intent data be ITT reserve would reviewed data with our of which
reminder, with all concerns data. not trial. GX did DMC a to as the And any blinded the express remains Importantly,
We for continue achieve outcome a of ability reasons. in the confident variety of trilaciclib to to a be positive
there final a alpha there the at at analysis. analysis [indiscernible] likelihood positive of number is First, allocation higher achieving a a events because a a outcome larger are greater of and final
of median data hazard II precedes the analysis, those be described receiving to prior that to provides able trial trilaciclib trial strength survival critical that results chemotherapy the additional detect compared at larger at patients receiving hazard the call statistically to discussed ratio the [ we the final to And larger the ] of ratio confidence. We up X.XX. pick last analysis the was ability This we'll interim. in of which critical this hazard a the on significant the course, to frequently gemcitabine We in in X.XX final overall ratio interim. in second, saw alone. compared improvements And the Phase carboplatin a
with curve until [indiscernible] of continue separate plus approximately patients tumors. to receiving XX participants capital gemcitabine for over prior separation chemotherapy, trilaciclib, curves the time participants to carboplatin trial their didn't particularly negative Importantly, survival occur to The PD-LX receiving months. compared placebo
enrollment until patient was interim the and period the was October particularly approximately February XXXX PRESERVE XX months in the enrolled. June analysis last for XXXX, is conducted relevant This X as from XXXX after
use trial. and continue therapy the follow-up Cancer the final analysis the of the December additional regarding between to subsequent with among curves important last that participated meaningfully compelling we separate. Symposium interim could the Therefore, TNBC anticancer results San be presented for year Breast II at to that in the in months Equally Antonio Phase patients
time receive therapy the was versus the the first after results carboplatin of a statistically not compared show survival X.XXX. XX.X in results provide to discontinuation Participants months. analysis months These subsequent during by was improvements trilaciclib trilaciclib immune were of X.X that who Further, for trilaciclib term, receive exhibited XX months also significant and short then The who patients benefits benefits for months These received administration surveillance. additional patients with did trilaciclib with they overall in with receive chemotherapy trilaciclib. subsequent who their from clinically anticancer this and for gemcitabine long-term can p-value discontinuation improving after p-value prior started X.XXX. XX.X meaningful median with median overall trilaciclib survival therapy
in of metastatic X.XX ratio achieved Given ratio population ITT in hazard biggest in would achieving hazard triple-negative pembrolizumab that X.XX in first-line overall of the mark improvement cancer [indiscernible] the a [indiscernible]. boundary the KEYNOTE-XXX our trial, survival breast
quarter the which look estimated of this final in We forward third the year. to to be are results,
median trial receiving January, historical described we Regarding initial ADC improvements trilaciclib [indiscernible]. the of efficacy including meaningful results among in to tralacitlib In overall sacituzumab for TROPX the ADC alone. II survival our with results combination promising patients compared in Phase
results midyear. survival overall to expect provide We updated
TROPX Assuming strong, in anticipate in trilaciclib the developing ADCs updated are in results partnership beyond. development various of remain clinical stages continued that TNBC we interest and with
along with trilaciclib benefits These Symposium study October are to continue known data analyses Quality combination ongoing, which survival according The also cut demonstrated real-world of clinical evidence is at survival and recent look II Additional associated may reductions prior and with most and studies the lung and in the of small topotecan in of would perspective ongoing we investigator-initiated mono potential include promising responses. benefit which myeloprotection where trilaciclib Lineberger tumor presented XXX Phase post-marketing already cancer at in cell the ASCO in investigator patients. cancer. protection to the cell stage generate, improve extensive trials The to supplement in a lurbinectedin, the small to survival the trilaciclib to costs. approximately tracking overall Care and in continues both evaluate of hospitalizations lung trial UNC study real-world was from the
on Phase results next the the we in However, TNBC Phase deliver III results science to the in cancer third X II quarter. as over advancing final months focus near-term clinical ADC remain our the triple-negative midyear breast the and
financial With to over John the call that, I'll for the results. turn
